Involvement of the adapter protein CRKL in integrin-mediated adhesion

CRKL, an SH2-SH3-SH3 adapter protein, is one of the major tyrosine phosphoproteins detected in primary leukemic neutrophils from patients with CML. CRKL binds directly to BCR/ABL through its N-terminal SH3 domain, suggesting it may be involved in BCR/ABL signal transduction. However, the biological...

Full description

Saved in:
Bibliographic Details
Published inOncogene Vol. 18; no. 22; pp. 3343 - 3353
Main Authors UEMURA, N, SALGIA, R, EWANIUK, D. S, LITTLE, M.-T, GRIFFIN, J. D
Format Journal Article
LanguageEnglish
Published Basingstoke Nature Publishing 03.06.1999
Nature Publishing Group
Subjects
Online AccessGet full text

Cover

Loading…
Abstract CRKL, an SH2-SH3-SH3 adapter protein, is one of the major tyrosine phosphoproteins detected in primary leukemic neutrophils from patients with CML. CRKL binds directly to BCR/ABL through its N-terminal SH3 domain, suggesting it may be involved in BCR/ABL signal transduction. However, the biological function of CRKL in either normal or leukemic cells is still largely unknown. In this study, we have examined the effects of overexpressing full length or deletion mutants of CRKL in hematopoietic cell lines. Full length, SH2- and SH3(N)-domain deletion mutants of CRKL were transfected into an interleukin-3-dependent hematopoietic cell line, Ba/F3, and 3-5 individual sublines which stably overexpressed each transgene were obtained [Ba/F-CRKL, Ba/F-CRKL deltaSH2, and Ba/F-CRKL deltaSH3(N)]. The growth properties of these transfected cells in the presence or absence of IL-3 were not different from mock transfected or untransfected Ba/F3 cells. However, Ba/F3 cells overexpressing full length CRKL, but not deletion mutants of CRKL, were found to have an increase in their ability to bind to fibronectin-coated surfaces. Further, expression of full length, but not deltaSH2- or deltaSH3-CRKL deletion mutants, was found to alter cell morphology on fibronectin-coated plates, an effect which was further enhanced by certain kinds of stress stimuli, such as ionizing radiation. Similar results were obtained when CRKL was transiently overexpressed in Ba/F3 cells, and were also obtained in a second IL-3 dependent hematopoietic cell line, 32Dcl3. Adhesion to fibronectin was blocked by anti-beta1 integrin monoclonal antibody, but overexpression of CRKL did not affect surface expression of beta1 integrins, nor did it spontaneously induce expression of the beta1 integrin 'activation' epitope recognized by the 9EG7 monoclonal antibody. These data suggest a role for CRKL in signaling pathways which regulate adhesion to fibronectin.
AbstractList CRKL, an SH2-SH3-SH3 adapter protein, is one of the major tyrosine phosphoproteins detected in primary leukemic neutrophils from patients with CML. CRKL binds directly to BCR/ABL through its N-terminal SH3 domain, suggesting it may be involved in BCR/ABL signal transduction. However, the biological function of CRKL in either normal or leukemic cells is still largely unknown. In this study, we have examined the effects of overexpressing full length or deletion mutants of CRKL in hematopoietic cell lines. Full length, SH2- and SH3(N)-domain deletion mutants of CRKL were transfected into an interleukin-3-dependent hematopoietic cell line, Ba/F3, and 3-5 individual sublines which stably overexpressed each transgene were obtained [Ba/ F-CRKL, Ba/F-CRKL Delta SH2, and Ba/F-CRKL Delta SH3(N)]. The growth properties of these transfected cells in the presence or absence of IL-3 were not different from mock transfected or untransfected Ba/F3 cells. However, Ba/F3 cells overexpressing full length CRKL, but not deletion mutants of CRKL, were found to have an increase in their ability to bind to fibronectin-coated surfaces. Further, expression of full length, but not Delta SH2- or Delta SH3-CRKL deletion mutants, was found to alter cell morphology on fibronectin-coated plates, an effect which was further enhanced by certain kinds of stress stimuli, such as ionizing radiation. Similar results were obtained when CRKL was transiently overexpressed in Ba/F3 cells, and were also obtained in a second IL-3 dependent hematopoietic cell line, 32Dcl3. Adhesion to fibronectin was blocked by anti- beta 1 integrin monoclonal antibody, but overexpression of CRKL did not affect surface expression of beta 1 integrins, nor did it spontaneously induce expression of the beta 1 integrin 'activation' epitope recognized by the 9EG7 monoclonal antibody. These data suggest a role for CRKL in signaling pathways which regulate adhesion to fibronectin.
CRKL, an SH2-SH3-SH3 adapter protein, is one of the major tyrosine phosphoproteins detected in primary leukemic neutrophils from patients with CML. CRKL binds directly to BCR/ABL through its N-terminal SH3 domain, suggesting it may be involved in BCR/ABL signal transduction. However, the biological function of CRKL in either normal or leukemic cells is still largely unknown. In this study, we have examined the effects of overexpressing full length or deletion mutants of CRKL in hematopoietic cell lines. Full length, SH2- and SH3(N)-domain deletion mutants of CRKL were transfected into an interleukin-3-dependent hematopoietic cell line, Ba/F3, and 3 – 5 individual sublines which stably overexpressed each transgene were obtained [Ba/F-CRKL, Ba/F-CRKLΔSH2, and Ba/F-CRKL ΔSH3(N)]. The growth properties of these transfected cells in the presence or absence of IL-3 were not different from mock transfected or untransfected Ba/F3 cells. However, Ba/F3 cells overexpressing full length CRKL, but not deletion mutants of CRKL, were found to have an increase in their ability to bind to fibronectin-coated surfaces. Further, expression of full length, but not ΔSH2- or ΔSH3-CRKL deletion mutants, was found to alter cell morphology on fibronectin-coated plates, an effect which was further enhanced by certain kinds of stress stimuli, such as ionizing radiation. Similar results were obtained when CRKL was transiently overexpressed in Ba/F3 cells, and were also obtained in a second IL-3 dependent hematopoietic cell line, 32Dcl3. Adhesion to fibronectin was blocked by anti-β1 integrin monoclonal antibody, but overexpression of CRKL did not affect surface expression of β1 integrins, nor did it spontaneously induce expression of the β1 integrin `activation' epitope recognized by the 9EG7 monoclonal antibody. These data suggest a role for CRKL in signaling pathways which regulate adhesion to fibronectin.
CRKL, an SH2-SH3-SH3 adapter protein, is one of the major tyrosine phosphoproteins detected in primary leukemic neutrophils from patients with CML. CRKL binds directly to BCR/ABL through its N-terminal SH3 domain, suggesting it may be involved in BCR/ABL signal transduction. However, the biological function of CRKL in either normal or leukemic cells is still largely unknown. In this study, we have examined the effects of overexpressing full length or deletion mutants of CRKL in hematopoietic cell lines. Full length, SH2- and SH3(N)-domain deletion mutants of CRKL were transfected into an interleukin-3-dependent hematopoietic cell line, Ba/F3, and 3-5 individual sublines which stably overexpressed each transgene were obtained [Ba/F-CRKL, Ba/F-CRKL deltaSH2, and Ba/F-CRKL deltaSH3(N)]. The growth properties of these transfected cells in the presence or absence of IL-3 were not different from mock transfected or untransfected Ba/F3 cells. However, Ba/F3 cells overexpressing full length CRKL, but not deletion mutants of CRKL, were found to have an increase in their ability to bind to fibronectin-coated surfaces. Further, expression of full length, but not deltaSH2- or deltaSH3-CRKL deletion mutants, was found to alter cell morphology on fibronectin-coated plates, an effect which was further enhanced by certain kinds of stress stimuli, such as ionizing radiation. Similar results were obtained when CRKL was transiently overexpressed in Ba/F3 cells, and were also obtained in a second IL-3 dependent hematopoietic cell line, 32Dcl3. Adhesion to fibronectin was blocked by anti-beta1 integrin monoclonal antibody, but overexpression of CRKL did not affect surface expression of beta1 integrins, nor did it spontaneously induce expression of the beta1 integrin 'activation' epitope recognized by the 9EG7 monoclonal antibody. These data suggest a role for CRKL in signaling pathways which regulate adhesion to fibronectin.
Author GRIFFIN, J. D
UEMURA, N
EWANIUK, D. S
SALGIA, R
LITTLE, M.-T
Author_xml – sequence: 1
  givenname: N
  surname: UEMURA
  fullname: UEMURA, N
  organization: Department of Adult Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, Massachusetts, MA 02115, United States
– sequence: 2
  givenname: R
  surname: SALGIA
  fullname: SALGIA, R
  organization: Department of Adult Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, Massachusetts, MA 02115, United States
– sequence: 3
  givenname: D. S
  surname: EWANIUK
  fullname: EWANIUK, D. S
  organization: Department of Adult Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, Massachusetts, MA 02115, United States
– sequence: 4
  givenname: M.-T
  surname: LITTLE
  fullname: LITTLE, M.-T
  organization: Department of Adult Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, Massachusetts, MA 02115, United States
– sequence: 5
  givenname: J. D
  surname: GRIFFIN
  fullname: GRIFFIN, J. D
  organization: Department of Adult Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, Massachusetts, MA 02115, United States
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1859199$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/10362355$$D View this record in MEDLINE/PubMed
BookMark eNqF0UlLAzEUB_AgFbvo1aMMKN6mZplkkqOUumBBED2HTOaNnTJNajIt-O2NtKB48fQuv_fnLWM0cN4BQucETwlm8iaupt7ZKaGYCqmO0IgUpcg5V8UAjbDiOFeU0SEax7jCGJcK0xM0TK2CMs5HaP7odr7bwRpcn_km65eQmdpsegjZJvgeWpfNXp4WWaqt6-E9tC5fQ92aHuoklxBb707RcWO6CGeHOkFvd_PX2UO-eL5_nN0uclsQ1efEME4pJaqqKW4aSSomuGiq0hBb89oQAyBZxerSKgukERyXVFhOFbdSCcMm6Hqfm0b72ELs9bqNFrrOOPDbqIWSWCjF_oUk5RasUAle_oErvw0uLaGTIFSWUsqkpntlg48xQKM3oV2b8KkJ1t9_0HGl0x_04Q-p4eIQu63StX7x_eETuDoAE63pmmCcbeOPk1yRtMgXVGGRZA
CitedBy_id crossref_primary_10_1074_jbc_M004627200
crossref_primary_10_3892_ijo_2014_2759
crossref_primary_10_1097_00029330_200703010_00007
crossref_primary_10_1016_j_hoc_2004_03_008
crossref_primary_10_1182_blood_V97_12_3768
crossref_primary_10_1016_S1359_6101_01_00029_6
crossref_primary_10_1182_blood_V95_8_2505
crossref_primary_10_1002_jcp_20694
crossref_primary_10_3389_fimmu_2015_00509
crossref_primary_10_1002_jcp_24412
crossref_primary_10_1182_blood_V99_7_2351
crossref_primary_10_1182_blood_V95_8_2505_008k24_2505_2513
crossref_primary_10_1263_jbb_103_444
crossref_primary_10_1080_15368378_2020_1846555
crossref_primary_10_1186_1478_811X_11_9
crossref_primary_10_1074_jbc_M102924200
crossref_primary_10_1074_jbc_274_53_37525
crossref_primary_10_1182_blood_2001_11_0032
crossref_primary_10_1146_annurev_immunol_22_012703_104649
crossref_primary_10_1002_cyto_a_20424
crossref_primary_10_1007_BF02981955
crossref_primary_10_1182_blood_2003_01_0062
crossref_primary_10_1038_s41392_021_00823_w
crossref_primary_10_1074_jbc_M210817200
crossref_primary_10_1189_jlb_71_3_425
Cites_doi 10.1073/pnas.90.19.9051
10.1038/374477a0
10.1074/jbc.270.25.15341
10.1182/blood.V84.9.2912.bloodjournal8492912
10.1101/gad.8.7.783
10.1042/bj3250375
10.1182/blood.V84.6.1731.1731
10.1006/bbrc.1997.7480
10.1128/MCB.18.5.3044
10.1006/excr.1996.3466
10.1074/jbc.270.37.21468
10.1074/jbc.270.49.29145
10.1074/jbc.270.10.5039
10.1128/MCB.12.8.3482
10.1074/jbc.271.41.25198
10.1172/JCI118820
10.1073/pnas.93.26.15174
10.1074/jbc.272.7.4230
10.1074/jbc.270.7.2893
10.1038/332272a0
10.1016/S0021-9258(17)31596-X
10.1002/j.1460-2075.1994.tb06518.x
10.1074/jbc.270.25.15398
10.2307/3578372
10.1007/978-1-4615-2994-1_14
10.1074/jbc.272.22.14320
10.1016/0092-8674(89)90985-9
10.1073/pnas.94.9.4463
10.1038/sj.leu.2400590
10.1002/j.1460-2075.1994.tb06684.x
10.1074/jbc.272.35.22215
10.1074/jbc.272.15.10248
10.1093/nar/18.17.5322
10.1128/MCB.16.4.1770
10.1128/MCB.13.8.4648
10.1182/blood.V87.1.73.73
10.1182/blood.V89.9.3166
10.1073/pnas.92.23.10678
10.1073/pnas.91.8.3443
10.1083/jcb.140.4.961
10.1002/bies.950161108
10.1074/jbc.271.38.23255
10.1002/j.1460-2075.1991.tb07693.x
10.1038/sj.onc.1200885
10.1128/MCB.18.9.5082
10.1016/S0021-9258(19)50057-6
10.1016/S0960-9822(95)00060-1
ContentType Journal Article
Copyright 1999 INIST-CNRS
Macmillan Publishers Limited 1999.
Copyright_xml – notice: 1999 INIST-CNRS
– notice: Macmillan Publishers Limited 1999.
DBID IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7TM
7TO
7U9
8FD
FR3
H94
K9.
P64
RC3
7X8
DOI 10.1038/sj.onc.1202689
DatabaseName Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Nucleic Acids Abstracts
Oncogenes and Growth Factors Abstracts
Virology and AIDS Abstracts
Technology Research Database
Engineering Research Database
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Biotechnology and BioEngineering Abstracts
Genetics Abstracts
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Genetics Abstracts
Virology and AIDS Abstracts
Oncogenes and Growth Factors Abstracts
Technology Research Database
Nucleic Acids Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Engineering Research Database
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitleList Oncogenes and Growth Factors Abstracts
Genetics Abstracts
MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Biology
EISSN 1476-5594
EndPage 3353
ExternalDocumentID 10_1038_sj_onc_1202689
10362355
1859199
Genre Research Support, U.S. Gov't, P.H.S
Journal Article
GrantInformation_xml – fundername: NIDDK NIH HHS
  grantid: DK560654
– fundername: NCI NIH HHS
  grantid: CA36167
GroupedDBID ---
-Q-
.55
.GJ
08R
0R~
123
29N
2WC
36B
39C
3O-
3V.
4.4
406
53G
5RE
70F
7X7
88A
88E
8AO
8C1
8FE
8FH
8FI
8FJ
8G5
8R4
8R5
AADWK
AANZL
AAPBV
AATNV
AAUGY
AAWBL
AAYFA
AAYJO
AAZLF
ABAWZ
ABDBF
ABEFU
ABGIJ
ABLJU
ABPTK
ABUWG
ACBMV
ACBRV
ACBYP
ACGFO
ACGFS
ACIGE
ACKTT
ACMJI
ACPRK
ACRQY
ACTTH
ACVWB
ADBBV
ADFRT
ADHDB
ADMDM
ADQMX
ADYYL
AEDAW
AEFTE
AEJRE
AENEX
AEVLU
AEXYK
AFFNX
AFKRA
AFNRJ
AFSHS
AGEZK
AGGBP
AGHAI
AHMBA
AHSBF
AILAN
AJCLW
AJDOV
AJRNO
ALFFA
ALMA_UNASSIGNED_HOLDINGS
AMRJV
AMYLF
ASPBG
AVWKF
AXYYD
AZFZN
AZQEC
B0M
BAWUL
BBNVY
BENPR
BHPHI
BKKNO
BPHCQ
BVXVI
CAG
CCPQU
COF
CS3
DIK
DNIVK
DPUIP
DU5
DWQXO
E3Z
EAD
EAP
EBC
EBD
EBLON
EBS
EE.
EIOEI
EJD
EMB
EMK
EMOBN
EPL
ESX
F5P
FDQFY
FEDTE
FERAY
FIZPM
FRP
FSGXE
FYUFA
GNUQQ
GUQSH
HCIFZ
HZ~
IAO
IHR
INH
INR
IQODW
ITC
IWAJR
JSO
JZLTJ
KQ8
L7B
LK8
M0L
M1P
M2O
M7P
N9A
NAO
NQJWS
NXXTH
NYICJ
O9-
OK1
OVD
P2P
PQQKQ
PROAC
PSQYO
Q2X
RNS
RNT
RNTTT
SNX
SNYQT
SOHCF
SRMVM
SV3
SWTZT
TAOOD
TBHMF
TDRGL
TEORI
TR2
TSG
TUS
UDS
UKHRP
W2D
WH7
X7M
ZA5
ZXP
~8M
AAYZH
ABAKF
ABJNI
ABZZP
ACAOD
ACZOJ
AEMSY
AFBBN
AGQEE
ALIPV
CGR
CUY
CVF
ECM
EIF
HVGLF
NPM
AAYXX
CITATION
7TM
7TO
7U9
8FD
FR3
H94
K9.
P64
RC3
7X8
ID FETCH-LOGICAL-c419t-1a3522219bd20ff81b3656fb7a1cd5da1aee83b3d7c9ce1f650726c5295c896a3
ISSN 0950-9232
IngestDate Fri Oct 25 01:50:17 EDT 2024
Fri Oct 25 23:55:09 EDT 2024
Thu Oct 10 19:20:30 EDT 2024
Thu Sep 26 19:16:53 EDT 2024
Tue Oct 15 23:17:18 EDT 2024
Sun Oct 29 17:07:24 EDT 2023
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 22
Keywords Rodentia
SH3 Domain
Adhesion
SH2 Domain
Signal transduction
Vertebrata
Mammalia
Integrin
Cell line
Mouse
C-Onc gene
Extracellular matrix
Mutation
Fusion protein
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c419t-1a3522219bd20ff81b3656fb7a1cd5da1aee83b3d7c9ce1f650726c5295c896a3
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
OpenAccessLink https://doi.org/10.1038/sj.onc.1202689
PMID 10362355
PQID 2641287888
PQPubID 36330
PageCount 11
ParticipantIDs proquest_miscellaneous_69806993
proquest_miscellaneous_17264349
proquest_journals_2641287888
crossref_primary_10_1038_sj_onc_1202689
pubmed_primary_10362355
pascalfrancis_primary_1859199
PublicationCentury 1900
PublicationDate 1999-06-03
PublicationDateYYYYMMDD 1999-06-03
PublicationDate_xml – month: 06
  year: 1999
  text: 1999-06-03
  day: 03
PublicationDecade 1990
PublicationPlace Basingstoke
PublicationPlace_xml – name: Basingstoke
– name: England
– name: New York
PublicationTitle Oncogene
PublicationTitleAlternate Oncogene
PublicationYear 1999
Publisher Nature Publishing
Nature Publishing Group
Publisher_xml – name: Nature Publishing
– name: Nature Publishing Group
References BF1202689_CR38
BF1202689_CR37
BF1202689_CR36
BF1202689_CR35
BF1202689_CR39
BF1202689_CR41
BF1202689_CR40
BF1202689_CR45
BF1202689_CR44
BF1202689_CR43
BF1202689_CR42
BF1202689_CR6
BF1202689_CR7
BF1202689_CR8
BF1202689_CR9
BF1202689_CR49
BF1202689_CR48
BF1202689_CR47
BF1202689_CR1
BF1202689_CR46
BF1202689_CR2
BF1202689_CR3
BF1202689_CR4
BF1202689_CR5
BF1202689_CR52
BF1202689_CR51
BF1202689_CR50
BF1202689_CR12
BF1202689_CR11
BF1202689_CR55
BF1202689_CR10
BF1202689_CR54
BF1202689_CR53
BF1202689_CR16
BF1202689_CR15
BF1202689_CR14
BF1202689_CR13
BF1202689_CR19
BF1202689_CR18
BF1202689_CR17
BF1202689_CR23
BF1202689_CR22
BF1202689_CR21
BF1202689_CR20
BF1202689_CR27
BF1202689_CR26
BF1202689_CR25
BF1202689_CR24
BF1202689_CR29
BF1202689_CR28
BF1202689_CR30
BF1202689_CR34
BF1202689_CR33
BF1202689_CR32
BF1202689_CR31
References_xml – ident: BF1202689_CR19
  doi: 10.1073/pnas.90.19.9051
– ident: BF1202689_CR36
  doi: 10.1038/374477a0
– ident: BF1202689_CR52
– ident: BF1202689_CR46
  doi: 10.1074/jbc.270.25.15341
– ident: BF1202689_CR28
  doi: 10.1182/blood.V84.9.2912.bloodjournal8492912
– ident: BF1202689_CR35
  doi: 10.1101/gad.8.7.783
– ident: BF1202689_CR5
  doi: 10.1042/bj3250375
– ident: BF1202689_CR51
  doi: 10.1182/blood.V84.6.1731.1731
– ident: BF1202689_CR8
  doi: 10.1006/bbrc.1997.7480
– ident: BF1202689_CR1
  doi: 10.1128/MCB.18.5.3044
– ident: BF1202689_CR34
  doi: 10.1006/excr.1996.3466
– ident: BF1202689_CR9
  doi: 10.1074/jbc.270.37.21468
– ident: BF1202689_CR41
  doi: 10.1074/jbc.270.49.29145
– ident: BF1202689_CR38
  doi: 10.1074/jbc.270.10.5039
– ident: BF1202689_CR42
– ident: BF1202689_CR23
  doi: 10.1128/MCB.12.8.3482
– ident: BF1202689_CR39
  doi: 10.1074/jbc.271.41.25198
– ident: BF1202689_CR4
  doi: 10.1172/JCI118820
– ident: BF1202689_CR20
  doi: 10.1073/pnas.93.26.15174
– ident: BF1202689_CR22
  doi: 10.1074/jbc.272.7.4230
– ident: BF1202689_CR45
  doi: 10.1074/jbc.270.7.2893
– ident: BF1202689_CR24
– ident: BF1202689_CR49
– ident: BF1202689_CR25
  doi: 10.1038/332272a0
– ident: BF1202689_CR30
  doi: 10.1016/S0021-9258(17)31596-X
– ident: BF1202689_CR11
  doi: 10.1002/j.1460-2075.1994.tb06518.x
– ident: BF1202689_CR29
  doi: 10.1074/jbc.270.25.15398
– ident: BF1202689_CR31
  doi: 10.2307/3578372
– ident: BF1202689_CR55
  doi: 10.1007/978-1-4615-2994-1_14
– ident: BF1202689_CR44
  doi: 10.1074/jbc.272.22.14320
– ident: BF1202689_CR17
  doi: 10.1016/0092-8674(89)90985-9
– ident: BF1202689_CR32
  doi: 10.1073/pnas.94.9.4463
– ident: BF1202689_CR54
  doi: 10.1038/sj.leu.2400590
– ident: BF1202689_CR37
  doi: 10.1002/j.1460-2075.1994.tb06684.x
– ident: BF1202689_CR2
– ident: BF1202689_CR14
  doi: 10.1074/jbc.272.35.22215
– ident: BF1202689_CR12
– ident: BF1202689_CR43
  doi: 10.1074/jbc.272.15.10248
– ident: BF1202689_CR27
  doi: 10.1093/nar/18.17.5322
– ident: BF1202689_CR13
  doi: 10.1128/MCB.16.4.1770
– ident: BF1202689_CR7
  doi: 10.1128/MCB.13.8.4648
– ident: BF1202689_CR15
  doi: 10.1182/blood.V87.1.73.73
– ident: BF1202689_CR40
– ident: BF1202689_CR3
  doi: 10.1182/blood.V89.9.3166
– ident: BF1202689_CR33
  doi: 10.1073/pnas.92.23.10678
– ident: BF1202689_CR53
– ident: BF1202689_CR50
  doi: 10.1073/pnas.91.8.3443
– ident: BF1202689_CR18
  doi: 10.1083/jcb.140.4.961
– ident: BF1202689_CR21
  doi: 10.1002/bies.950161108
– ident: BF1202689_CR47
  doi: 10.1074/jbc.271.38.23255
– ident: BF1202689_CR16
  doi: 10.1002/j.1460-2075.1991.tb07693.x
– ident: BF1202689_CR10
  doi: 10.1038/sj.onc.1200885
– ident: BF1202689_CR48
  doi: 10.1128/MCB.18.9.5082
– ident: BF1202689_CR6
  doi: 10.1016/S0021-9258(19)50057-6
– ident: BF1202689_CR26
  doi: 10.1016/S0960-9822(95)00060-1
SSID ssj0007902
Score 1.7705201
Snippet CRKL, an SH2-SH3-SH3 adapter protein, is one of the major tyrosine phosphoproteins detected in primary leukemic neutrophils from patients with CML. CRKL binds...
SourceID proquest
crossref
pubmed
pascalfrancis
SourceType Aggregation Database
Index Database
StartPage 3343
SubjectTerms Abl gene
Adapter proteins
Adaptor Proteins, Signal Transducing
Animals
BCR gene
BCR protein
Biological and medical sciences
Cell Adhesion - physiology
Cell interactions, adhesion
Cell Line
Cell lines
Cytology
Deletion mutant
Epitopes
Extracellular Matrix Proteins - metabolism
Fibronectin
Fibronectins - metabolism
Fundamental and applied biological sciences. Psychology
Hematopoietic Stem Cells - cytology
Hematopoietic Stem Cells - metabolism
Integrins
Interleukin 3
Interleukin-3 - metabolism
Ionizing radiation
Leukemia
Leukocytes (neutrophilic)
Mice
Molecular and cellular biology
Monoclonal antibodies
Mutants
Mutation
Nuclear Proteins - genetics
Nuclear Proteins - metabolism
Phosphoproteins
Recombinant Proteins - genetics
Recombinant Proteins - metabolism
Signal Transduction
Tyrosine
Title Involvement of the adapter protein CRKL in integrin-mediated adhesion
URI https://www.ncbi.nlm.nih.gov/pubmed/10362355
https://www.proquest.com/docview/2641287888
https://search.proquest.com/docview/17264349
https://search.proquest.com/docview/69806993
Volume 18
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF5BEVAJIQiFBlrwAYmTi-31a4-opGppaCWUSLmt1vugqcCOsC0Ev57Zh51YJeJxcSLbcayZ2dlvd2a-Qeg1YFTJWRH7iUiZH8PRJyxJfKW73hdFkBJh2D4v0tN5_GGRLNYt60x1SVMc8Z-_rSv5H63COdCrrpL9B832D4UT8B30C0fQMBz_SsdnJTgXQ_jddLF-JthK8x4a_gVd0ffpfKr3NCwtxLL0TamIhplMXMm604qDp5clr-DfemXP5dfWNCLaiNiwL59tgm0fI5p8Z-WyNW71_XordbrU9Mhmw9VlYgtXbUdMEhQe7BIGPmDALQ6z7aqKnfvD2HIuuakUY0sEfMNNW1L2-vqoAicYRrAOtH2EhnzYF5f0ZD6d0tlkMbuN7kTgSkwg_uy8n2szm1Xav2ZHy4nzt8OnD2DHgxWrYQQo27pk-9rCYIzZI_TQLQ68d1bTj9EtWY7QXdsu9McI3T_uuvON0L2PLiniCZpsmIFXKQ_MwHNm4Dkz8LQZePB5wwy8zgz20PxkMjs-9V13DJ_HIWn8kGnsDBNOIaJAKVh-YMDmqshYyEUiWMikzHGBRcYJl6ECKJ5FKdeBXZ6TlOGnaKesSrmPPFi1CpWDsy9YEseK5ykXOMIsFGkgkywYozed8OjKkqBQk7yAc1pfUxAzdWIeo8OBbNe3a55EAtcPOllTN5BqCpgcUJLeixmjV_1lkKeOXbFSVm1NAWcDdo7J9jtSkoNnIXiMnlkdbrwqoDTA1c__-NsXaHc9Cg7QTvOtlYcAOpvipbG7X2AOgT4
link.rule.ids 315,783,787,27936,27937
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Involvement+of+the+adapter+protein+CRKL+in+integrin-mediated+adhesion&rft.jtitle=Oncogene&rft.au=Uemura%2C+N&rft.au=Salgia%2C+R&rft.au=Ewaniuk%2C+D+S&rft.au=Little%2C+M+T&rft.date=1999-06-03&rft.issn=0950-9232&rft.volume=18&rft.issue=22&rft.spage=3343&rft.epage=3353&rft_id=info:doi/10.1038%2Fsj.onc.1202689&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0950-9232&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0950-9232&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0950-9232&client=summon